| 80.18 1.25 (1.58%) | 03-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 101.93 | 1-year : | 112.01 |
| Resists | First : | 87.27 | Second : | 95.9 |
| Pivot price | 79.93  |
|||
| Supports | First : | 73.3 | Second : | 60.99 |
| MAs | MA(5) : | 77.68 |
MA(20) : | 81.82 |
| MA(100) : | 76.21 |
MA(250) : | 55.95 |
|
| MACD | MACD : | -1.4 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 33.3 |
D(3) : | 20 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 103 | Low : | 19.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KYMR ] has closed below upper band by 47.8%. Bollinger Bands are 29.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 82.17 - 82.56 | 82.56 - 82.92 |
| Low: | 76.3 - 76.74 | 76.74 - 77.14 |
| Close: | 79.43 - 80.18 | 80.18 - 80.85 |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Wed, 25 Mar 2026
Kymera Therapeutics (NASDAQ:KYMR) COO Sells $7,063,662.50 in Stock - MarketBeat
Wed, 25 Mar 2026
Jeremy Chadwick Sells 24,727 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Wed, 25 Mar 2026
Kymera Therapeutics (NASDAQ:KYMR) Shares Up 8.4% - What's Next? - MarketBeat
Tue, 24 Mar 2026
Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - MSN
Tue, 24 Mar 2026
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 5.442e+007 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 8,650 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.3883e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 411 % |
| Return on Equity (ttm) | -15.9 % |
| Qtrly Rev. Growth | 3.921e+007 % |
| Gross Profit (p.s.) | -26.61 |
| Sales Per Share | -11.21 |
| EBITDA (p.s.) | -1.20591e+008 |
| Qtrly Earnings Growth | -3.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -233 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -7.16 |
| Price to Cash Flow | 9.49 |
| Dividend | 0 |
| Forward Dividend | 9.81e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|